{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valchlor&page=97",
    "query": {
      "intervention": "Valchlor",
      "page": 97
    },
    "page_size": 10
  },
  "pagination": {
    "page": 97,
    "page_size": 10,
    "total_count": 3022,
    "total_pages": 303,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valchlor&page=98&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Valchlor&page=96&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T03:26:18.226Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06026319",
      "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-hodgkin Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
        "High-grade B-cell Lymphoma",
        "Grade 3b Follicular Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "CD79b-19 CAR T cells",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marcela V. Maus, M.D.,Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-10-26",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026319"
    },
    {
      "nct_id": "NCT05052528",
      "title": "Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2021-09-17",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05052528"
    },
    {
      "nct_id": "NCT00577122",
      "title": "Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-negative Breast Cancer",
        "Progesterone Receptor-negative Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Medroxyprogesterone progesterone acetate (MPA)",
          "type": "DRUG"
        },
        {
          "name": "Medroxyprogesterone with Cyclophosphamide + Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-07",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577122"
    },
    {
      "nct_id": "NCT00004001",
      "title": "S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "estramustine",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 770,
      "start_date": "1999-10",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2014-02-25",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 16,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 13 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004001"
    },
    {
      "nct_id": "NCT01962636",
      "title": "Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Acute Lymphocytic Leukemia (ALL)",
        "Chronic Myelogenous Leukemia",
        "Plasma Cell Leukemia",
        "Myelofibrosis",
        "Myelodysplasia",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Marginal Zone B-Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-Cell Lymphoma",
        "Prolymphocytic Leukemia",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoblastic Lymphoma",
        "Burkitt's Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cyclosporine A",
          "type": "DRUG"
        },
        {
          "name": "Mycophenylate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Umbilical cord blood",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 200,
      "start_date": "2016-12",
      "completion_date": "2026-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962636"
    },
    {
      "nct_id": "NCT04678401",
      "title": "IS-free Treg HaploHCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stem Cell Transplant Complications",
        "Graft Vs Host Disease",
        "Myeloid Leukemia, Acute",
        "Myeloid Leukemia in Relapse (Disorder)",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Treg-enriched donor cell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Unmodified donor T Cell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CD34+ Haplo Peripheral Blood Stem Cell",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-01-12",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04678401"
    },
    {
      "nct_id": "NCT07341867",
      "title": "Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Triple Negative Breast Cancer",
        "Duffy Blood Group, Chemokine Receptor Gene Mutation",
        "Duffy Blood Group, Chemokine Receptor Gene C.-67T>C"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "LENALIDOMIDE",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Hantel, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-07-30",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07341867"
    },
    {
      "nct_id": "NCT05675410",
      "title": "A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bleomycin Sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Involved-site Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Procarbazine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Vinblastine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "5 Years to 60 Years"
      },
      "enrollment_count": 1875,
      "start_date": "2023-05-11",
      "completion_date": "2031-04-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 404,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05675410"
    },
    {
      "nct_id": "NCT05618925",
      "title": "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin's Lymphoma Refractory/Relapsed"
      ],
      "interventions": [
        {
          "name": "N803",
          "type": "DRUG"
        },
        {
          "name": "CD19t-haNK suspension",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-08-22",
      "completion_date": "2027-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Tyler, Texas",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05618925"
    },
    {
      "nct_id": "NCT02771197",
      "title": "Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northside Hospital, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-09-28",
      "completion_date": "2023-07-31",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-11-10T03:26:18.226Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02771197"
    }
  ]
}